Botulinum toxin a in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial

Zoe Apalla, Elena Sotiriou, Aimilios Lallas, Elizabeth Lazaridou, Demetrios Ioannides

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P

Original languageEnglish
Pages (from-to)857-864
Number of pages8
JournalClinical Journal of Pain
Volume29
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Postherpetic Neuralgia
Botulinum Toxins
Visual Analog Scale
Placebos
Type A Botulinum Toxins
Sleep
Maintenance
Safety
Pain

Keywords

  • Botulinum toxin
  • Herpes zoster
  • Neuropathic pain
  • Postherpetic neuralgia
  • Randomized clinical trial

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Botulinum toxin a in postherpetic neuralgia : A parallel, randomized, double-blind, single-dose, placebo-controlled trial. / Apalla, Zoe; Sotiriou, Elena; Lallas, Aimilios; Lazaridou, Elizabeth; Ioannides, Demetrios.

In: Clinical Journal of Pain, Vol. 29, No. 10, 10.2013, p. 857-864.

Research output: Contribution to journalArticle

Apalla, Zoe ; Sotiriou, Elena ; Lallas, Aimilios ; Lazaridou, Elizabeth ; Ioannides, Demetrios. / Botulinum toxin a in postherpetic neuralgia : A parallel, randomized, double-blind, single-dose, placebo-controlled trial. In: Clinical Journal of Pain. 2013 ; Vol. 29, No. 10. pp. 857-864.
@article{23932d7fe1464af88a9b69e08531547e,
title = "Botulinum toxin a in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial",
abstract = "Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50{\%} reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50{\%} maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50{\%} reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95{\%} CI, 2-1; ARR=0.87, 95{\%} CI, 055-096; P",
keywords = "Botulinum toxin, Herpes zoster, Neuropathic pain, Postherpetic neuralgia, Randomized clinical trial",
author = "Zoe Apalla and Elena Sotiriou and Aimilios Lallas and Elizabeth Lazaridou and Demetrios Ioannides",
year = "2013",
month = "10",
doi = "10.1097/AJP.0b013e31827a72d2",
language = "English",
volume = "29",
pages = "857--864",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Botulinum toxin a in postherpetic neuralgia

T2 - A parallel, randomized, double-blind, single-dose, placebo-controlled trial

AU - Apalla, Zoe

AU - Sotiriou, Elena

AU - Lallas, Aimilios

AU - Lazaridou, Elizabeth

AU - Ioannides, Demetrios

PY - 2013/10

Y1 - 2013/10

N2 - Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P

AB - Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P

KW - Botulinum toxin

KW - Herpes zoster

KW - Neuropathic pain

KW - Postherpetic neuralgia

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84888005745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888005745&partnerID=8YFLogxK

U2 - 10.1097/AJP.0b013e31827a72d2

DO - 10.1097/AJP.0b013e31827a72d2

M3 - Article

C2 - 23370074

AN - SCOPUS:84888005745

VL - 29

SP - 857

EP - 864

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 10

ER -